CTOs on the Move

ESSA Pharma

www.essapharma.com

 
As a clinical-stage pharmaceutical company founded on cutting-edge research, ESSA is focused on developing novel therapeutics for cancer patients. ESSA embraces innovation not only in our products but also in our approach. We re firmly rooted in creative and open thinking, giving us an energy and approach that makes us a different kind of pharmaceutical company.
  • Number of Employees: 25-100
  • Annual Revenue: $50-100 Million
  • www.essapharma.com
  • 700 Milam Street Suite 1300
    Houston, TX USA 77002
  • Phone: 832.871.5094

Executives

Name Title Contact Details

Funding

ESSA Pharma raised $36M on 08/27/2019
ESSA Pharma raised $10M on 01/12/2021
ESSA Pharma raised $130M on 02/22/2021

Similar Companies

NovaTec Consultants

NovaTec Consultants, Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioConvergence

BioConvergence is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

True North Therapeutics

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.

BNBI

Managed by Battelle National Biodefense Institute (BNBI) as a Federally Funded Research and Development Center (FFRDC), National Biodefense Analysis and Countermeasures Center is the first laboratory built for DHS – a national resource to understand th...

BioMarin

BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. We remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. Time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. The efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. Our track record of developing and commercializing new treatments has been significantly faster than the industry average and is a remarkable accomplishment that is ingrained in our culture. The company`s product portfolio comprises five marketed products and multiple clinical and pre-clinical product candidates.